Actions
Pages
Subscribe for newsletter
Stories
Moonwalk Biosciences, co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis, has secured $57 million in funding to advance gene therapy with its epigenetic editing technology.
The gene therapy market, set to surge from $7.18 billion in 2024 to $24.67 billion by 2029, continues to innovate with Moonwalk's non-invasive epigenetic editing. This method, targeting epigenetic modifications over DNA alteration, provides safer, more effective treatments for chronic and aging-related diseases.
“Epigenetics is the software of the genome. While changes to the genome are irreversible, edits to the epigenome can be reprogrammed in different ways. Epigenetic changes determine whether genes are turned on or off, and can potentially reverse disease, broadening the therapeutic landscape to find potential cures previously thought impossible,” said Alex Aravanis, M.D., Ph.D., CEO and Co-Founder, Moonwalk Biosciences.
The next steps include clinical trials to validate the safety and efficacy of its epigenetic editing technique. As this technology advances, it could challenge the industry's belief that traditional gene editing, such as CRISPR-Cas9, is the only path forward for gene therapy.
Moonwalk's approach, utilizing AI for predicting epigenetic targets, leverages the body's natural regulation system, offering a nuanced approach to gene control. This resonates with the trend in biotechnology towards precision and personalization, moving away from one-size-fits-all solutions.
Story
Chinese researchers have innovated a new electrode material for electrochemical extraction designed to attract uranium ions from seawater more efficiently than current methods.
It is estimated that there are 4.5 billion tons of uranium in the ocean as dissolved uranyl ions, over 1,000 times more than on land. The new electrode extraction technology enables harvesting of low-concentration uranium from seawater, about 3 parts per billion, promising a stable and cost-effective uranium supply.
The next steps involve scaling up this technology for industrial use and reducing costs to compete with traditional mining. The method, while promising, still faces challenges in terms of efficiency and environmental impact mitigation.
The global reliance on a limited number of uranium mines, often in politically sensitive areas, has long been a concern. This breakthrough could redistribute the geopolitical power dynamics in energy resources.
Story
Nanomedicine enables targeted drug delivery at the molecular and cellular levels. This precision allows for the delivery of therapeutic agents directly to the affected cells or tissues and can minimize side effects. Taiwan Liposome Company (TLC) is a clinical-stage biotech firm dedicated to developing and commercializing nanomedicines. Their focus is a proprietary lipid-assembled drug delivery platform using approved active pharmaceutical ingredients (APIs).
The nanomedicine industry is on a growth trajectory, projected to reach $358 billion by 2032.
TLC leverages the streamlined 505(b)(2) regulatory pathway in the United States due to its use of already approved APIs. This simplifies the approval process for their product candidates. TLC's collaborations with Endo and 3SBio for commercialization and regulatory approvals in new markets will expand its global footprint.
Expect TLC to leverage its proprietary technologies and partnerships to launch innovative products in key markets. The focus will be on expanding its customer base and navigating regulatory landscapes to deliver advanced therapies to more patients worldwide.
Story
Innovators
Scroll
Open
Close